| Literature DB >> 21092134 |
Tonny V Veenith1, Asmat H Din, Danielle Mj Eaton, Rowan M Burnstein.
Abstract
Strokes and TIAs, with their high cumulative mortality and morbidity rates, are occurring with increasing frequency in western population 14. As such, it is vital for clinicians to provide optimal medical management in the perioperative period for those patients with this common neurological problem. This review aims to highlight the importance of the perioperative period and the stages of pre-optimization that can be taken by the multi-disciplinary team to aid this 171819. The evidence suggests that there are significant physiological advantages to early invasive monitoring and high dependency care in these complex patients. These cohort of patients are at increased risk of development of respiratory, gastrointestinal, nutritional and electrolyte disturbances so a constant vigil should be exercised in early recognition and treatment.Entities:
Year: 2010 PMID: 21092134 PMCID: PMC3012661 DOI: 10.1186/1755-7682-3-33
Source DB: PubMed Journal: Int Arch Med ISSN: 1755-7682
Figure 1Showing a perfusion scan and a CT scan of a patient with a Left middle cerebral artery infarct [12][modified from reference [13]].
Underlying mechanisms of haemorrhagic and ischaemic stroke 3
| Ischaemic stroke | Haemorrhagic stroke |
|---|---|
| Thrombus - from a ulcerated plaque in the carotid artery | Hypertension is the commonest - causing weakness of the vessel wall |
| Cardioembolism from Atrial fibrillation (AF) | Amyloid angiopathy |
| Large vessel atherosclerosis causing a stroke by occlusion | Use of sympathomimetic drugs such as cocaine causing transient hypertension |
| Small deep perforating vessel arthrosclerosis causing lacunar stroke | Congenital Arterio-venous malformations, aneurysms |
| A venous clot, causing paradoxical embolism through a patent foramen ovale (PFO) | Uncommon such as tumours, vasculitis, bleeding diathesis and use of anticoagulants |
| Vasospasm of structurally normal vessels (e.g. sympathomimetic drug use) | |
| Hypercoagulable state, operating with any of these mechanisms or independently | |
Risk factors for the development of stroke 3578910
| Ischaemic stroke | Haemorrhagic stroke |
|---|---|
Predictors of death for the haemorrhagic (predicting death and disability at 30 days) and ischaemic strokes (death and disability at 100 days) 611
| Haemorrhagic stroke | Ischaemic stroke | |
|---|---|---|
| Size and location | The volume of ICH and location | Right and left arm paresis at admission, lenticulostriate infarction |
| Premorbid status | Age, sex, prior stroke and Diabetes | |
| Severity at presentation | The Glasgow Coma Scale (GCS) on admission | National institutes of health Stroke Scale at admission and Rankin Scale 48-72 hours later |
| Complications | Hydrocephalus | Fever, neurological complications. |
Favourable predictors of ischaemic and haemorrhagic stroke 4
| Haemorrhagic stroke | Ischaemic stroke |
|---|---|
| Cortical location | Location and good function at presentation |
| Mild neurological dysfunction | Mild neurological dysfunction |
| Low fibrinogen levels | Absence of AF as this predicts more Cardiovascular deaths |
Risk factors increasing mortality following TIA
| Previous strokes |
| Stroke in heavy smokers - > 40 per day (level comes to normal after 5 years of stopping) |
| Atrial Fibrillation -increasing risk about 5-fold |
| Diabetes, hypertension, MI and high cholesterol |
| Race - African American race has higher incidence |
| Conjugate equine oestrogen increased risk of ischemic stroke and TIAs by 55% |
Reduction strategies for the prevention of TIA and ischaemic strokes
| Strategy | Evidence | |
|---|---|---|
| Hypertension | Class I, Level of Evidence A, Benefit has been associated with an average reduction of &10/5 mm Hg (Normal defined by JNC 7 criteria as 120/80 mmHg). Drugs should be optimised to the target patient (consider the cardiac history, DM etc) | |
| Diabetes mellitus | Class I, Level of Evidence A, Rigorous control of hypertension and intensive lipid lowering treatment, any drugs appropriate and most often > 1 drug needed. | |
| Hypercholesterolemia | Class I, Level of Evidence A, Lifestyle modification, dietary guidelines and statins | |
| Cigarette Smoking | Class I, Level of Evidence C, Strongly advise every patient with stroke or TIA to quit | |
| Alcohol Intake | Class I, Level of Evidence A. Heavy drinkers should eliminate or reduce their consumption of alcohol.(it is actually a J-shaped association between alcohol and ischemic stroke, with a protective effect in light or moderate drinkers and an elevated stroke risk with heavy alcohol consumption) | |
| Obesity | Class IIb, Level of Evidence C. BMI of between 18.5 and 24.9 kg/m2 and a waist circumference of < 35 in for women and < 40 in for men | |
| Physical inactivity | Class IIb, Level of Evidence C. At least 30 minutes of moderate-intensity physical exercise | |
| Carotid endartrectomy(CEA) | Class I, Level of Evidence A. TIA or ischemic stroke within the last6 months and severe (70% to 99%) carotid artery stenosis, CEA by a surgeon with a peri-operative morbidity and mortality of < 6%. Consider CEA for certain high risk candidates with moderate stenosis (50-99%). If the TIA preferably within 2 weeks of after TIA. | |
| Extracranial Vertebrobasilar Disease/Intracranial Atherosclerosis | Class IIb, Level of Evidence C Endovascular treatment - when patients are having symptoms despite medical therapies | |
| Cardiogenic Embolism and PAF | Class I, Level of Evidence A, paroxysmal (intermittent) AF, anticoagulation with adjusted-Dose Warfarin (target INR, 2.5; range, 2.0 to 3.0). Aspirin to be given in those patients with a clear contra-indication to Warfarin. | |
| Cardiogenic Embolism - LV thrombus | Oral anticoagulation is reasonable, aiming for an INR of 2.0 to 3.0 for at least 3 months and up to 1 year (Class IIa, Level of Evidence B) | |
| Noncardioembolic ischemic stroke or TIA | (Class IIa, Level of Evidence A) Aspirin (50 to 325 mg/d), the combination of aspirin and extended-release dipyridamole, and clopidogrel are all acceptable options for initial therapy. Aspirin to clopidogrel increases the risk of haemorrhage and is not routinely recommended for ischemic stroke or TIA patients (Class III, Level of Evidence A). | |
| Patent Foramen Ovale | PFO closure may be considered for patients with recurrent cryptogenic stroke despite optimal medical therapy (Class IIb, Level of Evidence C) | |